IGF1R and Hyperinsulinemia: Despite the importance of IGF1R as an anti-cancer target, the clinical benefits of IGF1R inhibitors are still limited mainly due to hyperinsulinemia and hyperglycemia toxicity (reviewed in Reference [88]).